We can’t show the full text here under this license. Use the link below to read it at the source.
Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2
Immune response and protection from self-amplifying versus circular mRNA COVID-19 vaccines
AI simplified
Abstract
Both SAM-RBD and Circ-RBD vaccines induced comparable anti-RBD IgG and virus-neutralizing antibody titers.
- Circ-RBD vaccines generated a higher memory T cell response compared to SAM-RBD vaccines.
- Circ-RBD vaccine remains stable for 4 weeks at 4°C.
- A bivalent Circ-RBD vaccine effectively neutralized both delta and omicron variants of SARS-CoV-2.
- Circ-RNA-RBD presents a promising candidate for COVID-19 vaccination.
- The findings support the potential of Circ-RNA vaccines for developing against rapidly emerging viral variants.
AI simplified